DANAHER CORPORATION's ticker is DHR and the CUSIP is 235851102. A total of 2,042 filers reported holding DANAHER CORPORATION in Q3 2023. The put-call ratio across all filers is 0.89 and the average weighting 0.6%.
About DANAHER CORPORATION
Danaher Corporation is a global science and technology company that designs, manufactures, and markets innovative products and services to professional, medical, industrial, and commercial customers. The company operates through four segments: Life Sciences, Diagnostics, Dental, and Environmental & Applied Solutions.
Danaher's Life Sciences segment provides a range of research tools to scientists around the world, including mass spectrometry, chromatography, and automation systems. The Diagnostics segment offers a broad range of diagnostic products, including clinical chemistry, immunoassay, microbiology, and molecular diagnostic systems. The Dental segment provides a range of dental equipment and consumables, including imaging systems, dental instruments, and consumables. The Environmental & Applied Solutions segment offers a range of products and services to help customers protect the environment and improve productivity.
Danaher has a strong track record of growth and innovation, driven by its focus on continuous improvement and customer satisfaction. The company has a culture of operational excellence, which has enabled it to consistently deliver high-quality products and services to its customers. Danaher's management team is highly experienced and has a proven track record of creating value for shareholders.
In conclusion, Danaher Corporation is a well-established and innovative company that is well-positioned to continue delivering strong growth and value to its shareholders. With its focus on operational excellence and customer satisfaction, Danaher is a company that investors should keep an eye on.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $201,942,484 | +23.4% | 768,911 | +19.0% | 0.26% | +26.3% |
| Q2 2023 | $163,672,800 | -5.0% | 646,033 | +3.0% | 0.20% | -15.3% |
| Q1 2023 | $172,363,099 | +21.2% | 627,046 | +29.4% | 0.24% | +11.0% |
| Q4 2022 | $142,256,892 | -99.9% | 484,489 | +6.0% | 0.22% | +4.8% |
| Q3 2022 | $130,206,055,000 | +68.1% | 457,182 | +74.1% | 0.21% | +71.9% |
| Q2 2022 | $77,480,275,000 | -27.2% | 262,553 | -22.5% | 0.12% | -15.4% |
| Q1 2022 | $106,494,923,000 | -3.6% | 338,701 | +10.5% | 0.14% | -8.9% |
| Q4 2021 | $110,478,268,000 | -20.6% | 306,585 | -26.6% | 0.16% | -20.3% |
| Q3 2021 | $139,091,938,000 | +12.5% | 417,476 | -4.8% | 0.20% | +20.1% |
| Q2 2021 | $123,589,978,000 | -25.4% | 438,461 | -39.0% | 0.16% | -32.5% |
| Q1 2021 | $165,729,780,000 | +42.3% | 718,693 | +66.4% | 0.24% | +12.0% |
| Q4 2020 | $116,472,445,000 | +33.6% | 431,953 | +35.8% | 0.22% | +73.6% |
| Q3 2020 | $87,153,741,000 | -36.7% | 318,120 | -53.9% | 0.12% | -48.6% |
| Q2 2020 | $137,693,277,000 | +19.7% | 689,477 | -7.3% | 0.24% | +3.0% |
| Q1 2020 | $115,038,364,000 | +37.1% | 744,022 | +196.4% | 0.24% | +55.3% |
| Q4 2019 | $83,926,394,000 | +20.7% | 251,011 | +25.8% | 0.15% | +23.6% |
| Q3 2019 | $69,551,422,000 | -19.6% | 199,507 | -32.2% | 0.12% | -28.9% |
| Q2 2019 | $86,513,907,000 | +23.3% | 294,372 | +8.8% | 0.17% | +14.6% |
| Q1 2019 | $70,169,554,000 | +36.7% | 270,543 | +12.9% | 0.15% | +23.8% |
| Q4 2018 | $51,332,724,000 | -51.2% | 239,703 | -68.8% | 0.12% | -21.3% |
| Q3 2018 | $105,294,039,000 | +87.7% | 769,340 | +73.8% | 0.16% | +64.9% |
| Q2 2018 | $56,109,546,000 | +21.4% | 442,673 | -6.2% | 0.09% | +9.3% |
| Q1 2018 | $46,210,485,000 | -37.4% | 471,969 | -40.7% | 0.09% | -34.4% |
| Q4 2017 | $73,821,974,000 | -11.1% | 795,324 | -17.6% | 0.13% | -35.1% |
| Q3 2017 | $83,008,681,000 | +85.2% | 964,828 | +83.3% | 0.20% | +49.6% |
| Q2 2017 | $44,824,349,000 | -18.7% | 526,344 | -17.2% | 0.14% | -7.5% |
| Q1 2017 | $55,159,544,000 | +83.1% | 635,732 | +68.7% | 0.15% | +3.5% |
| Q4 2016 | $30,117,851,000 | +92.8% | 376,902 | +89.1% | 0.14% | +120.3% |
| Q3 2016 | $15,625,009,000 | -27.9% | 199,324 | -7.2% | 0.06% | -34.7% |
| Q2 2016 | $21,686,316,000 | -17.7% | 214,716 | -22.7% | 0.10% | -12.5% |
| Q1 2016 | $26,361,121,000 | -12.1% | 277,895 | -14.0% | 0.11% | +53.4% |
| Q4 2015 | $30,000,704,000 | +25.4% | 323,005 | +15.1% | 0.07% | +21.7% |
| Q3 2015 | $23,916,146,000 | -76.0% | 280,673 | -75.9% | 0.06% | -78.4% |
| Q2 2015 | $99,800,421,000 | +352.5% | 1,166,026 | +348.8% | 0.28% | +355.7% |
| Q1 2015 | $22,056,851,000 | -22.1% | 259,798 | -21.4% | 0.06% | -39.0% |
| Q4 2014 | $28,331,612,000 | -4.9% | 330,552 | -13.9% | 0.10% | +284.6% |
| Q3 2014 | $29,790,376,000 | +56.6% | 383,882 | +58.9% | 0.03% | +44.4% |
| Q2 2014 | $19,024,161,000 | -15.5% | 241,638 | -21.2% | 0.02% | +5.9% |
| Q1 2014 | $22,501,000,000 | -57.6% | 306,637 | -53.8% | 0.02% | -15.0% |
| Q4 2013 | $53,035,436,000 | +107.8% | 663,996 | +83.4% | 0.02% | +11.1% |
| Q3 2013 | $25,527,675,000 | +1482.6% | 361,993 | +1523.0% | 0.02% | +1700.0% |
| Q2 2013 | $1,613,070,000 | – | 22,304 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ARTHUR M. COHEN & ASSOCIATES, LLC | 217,436 | $53,823,432 | 13.80% |
| Defender Capital, LLC. | 152,962 | $37,949,802 | 13.74% |
| Bancreek Capital Management, LP | 60,890 | $15,106,809 | 13.58% |
| BOONE CAPITAL MANAGEMENT LLC | 129,163 | $32,045,340 | 10.11% |
| Eagle Health Investments LP | 175,085 | $43,438,589 | 9.57% |
| Third Point | 2,450,000 | $607,845,000 | 9.22% |
| Clio Asset Management LLC | 41,695 | $10,344,530 | 9.04% |
| Consulta Ltd | 500,000 | $124,050,000 | 8.91% |
| Riverstone Advisors, LLC | 47,960 | $11,799,701 | 8.16% |
| CADEN CAPITAL PARTNERS, LP | 123,755 | $27,215,377 | 7.66% |